IGMS: IGM Biosciences, Inc.

Stock

About

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Website
www.igmbio.com
Year Founded
2010
Employees
216
Sector
Health Care
HQ Location
Mountain View, CA

Current Value

$9.35

1 Year Return

$3.45
58.47%

Key Details

Market Cap

$567.29M

P/E Ratio

-2.61

1Y Stock Return

67.37%

1Y Revenue Growth

57.64%

Dividend Yield

0.00%

Price to Book

7.2

Strategies that include
IGMS

Medium risk

$13,000

Health Care Sector

growth
balanced
growth income

This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.

Top Sector

Health Care

Top Holdings

Return

+8.40%

Expense Ratio

0.00%

Holdings

331

Create your own
strategy with

IGMS
Three dimensional double logo

Stock's related to
IGMS

Correlated Stocks

NameCorrelationMarket CapReturn % (1 Year)Div Yield %
ABCL38.11%$800.44M-37.56%0.00%
VIR34.75%$954.40M-26.51%0.00%
FATE34.03%$248.29M-11.02%0.00%
CLFD33.10%$398.66M+4.48%0.00%
MEI32.90%$326.37M-60.53%6.06%
ZYME31.82%$1.03B+79.68%0.00%
RLAY31.72%$803.44M-39.70%0.00%
WBX31.41%$145.62M-57.82%0.00%
LAW31.27%$325.90M-3.37%0.00%
NNOX31.16%$332.87M-7.63%0.00%
TVTX31.14%$1.51B+207.79%0.00%
SHLS30.91%$691.80M-70.53%0.00%
GBIO30.88%$92.84M+20.87%0.00%
SCVL30.77%$914.94M+41.95%1.57%
SOL30.52%$98.11M-29.01%0.00%
PSTX30.42%$269.98M+6.13%0.00%
BNTX30.07%$25.51B+9.51%0.00%
CLNE29.92%$589.93M-23.92%0.00%
ULH29.78%$1.25B+97.14%0.88%
HCAT29.50%$458.79M0.00%0.00%

Uncorrelated Stocks

NameCorrelationMarket CapReturn % (1 Year)Div Yield %
LPLA-<0.01%$23.55B+38.13%0.38%
JBSS-0.03%$949.98M-9.36%1.04%
MSB-0.04%$337.71M+30.73%5.15%
FATBB0.04%$81.94M-12.91%11.69%
PSEC0.05%--15.48%
ARC-0.05%$146.66M+18.95%5.90%
RACE-0.06%$76.87B+18.66%0.61%
NLOP-0.08%$458.04M+94.60%0.00%
OCFT0.09%$80.95M-30.38%0.00%
MOH-0.10%$16.16B-21.56%0.00%
OXBR-0.12%$19.05M+178.18%0.00%
TPB-0.13%$1.08B+167.44%0.45%
HUSA-0.15%$16.69M-11.56%0.00%
VTYX-0.15%$125.87M-23.61%0.00%
RAMP0.18%$1.86B-16.17%0.00%
AXS0.19%$7.14B+55.12%2.06%
TMUS0.19%$270.63B+56.92%0.83%
META0.20%$1.42T+66.51%0.27%
BXSL-0.22%--9.81%
ERIE0.23%$19.39B+46.23%1.23%

ETF's related to
IGMS

News

Yahoo

IGM Biosciences ( NASDAQ:IGMS ) Third Quarter 2024 Results Key Financial Results Net loss: US$61.4m (flat on 3Q 2023...

Yahoo

IGM Biosciences (IGMS) delivered earnings and revenue surprises of -23.17% and 123.38%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Yahoo

– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for generalized myasthenia gravis by year-end 2024 – – Cash runway expected to fund operations into 2027 – MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies

Finnhub

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Imvotamab trials in rheumatoid arthritis, systemic lupus erythematosus and myositis...

Yahoo

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, IGM Biosciences...

Yahoo

MOUNTAIN VIEW, Calif., Nov. 04, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today announced that management will present at three upcoming investor conferences: Guggenheim Healthcare Innovation Conference on Monday, November 11 at 11:30 a.m. EST in BostonStifel Healthcare Conference on Tuesday, November 19 at 12:40 p.m. EST in New YorkJefferies London Healthcare Conference on Thursday, No

Disclaimer

Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.

Design your own stock index

© Double Finance, 2024

Double is a registered investment adviser with the US Securities and Exchange Commission (SEC). While such registration does not imply a certain level of skill, it does require us to follow federal regulations that protect you, the investor. By law, we must provide investment advice that is in the best interest of our client. Please refer to Double's Form CRS for important additional information.

The publicly available portions of the Platform (i.e., the sections of the Platform that are available to individuals who are not party to a Client Agreement - including double.finance) are provided for educational purposes only and are not intended to provide legal, tax, or financial planning advice. To the extent that any of the content published on publicly available portions of the Platform may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Nothing on the publicly available portions of the Platform should be construed as a solicitation or offer, or recommendation, to buy or sell any security. All charts, figures, and graphs on the publicly available websites are for illustrative purposes only. Before investing, you should consider whether any investment, investment strategy, security, other asset, or related transaction is appropriate for you based on your personal investment objectives, financial circumstances, and risk tolerance. You are also encouraged to consult your legal, tax, or investment professional regarding your specific situation. Registration does not imply a certain level of skill or training.

Investing involves risk. The value of your investment will fluctuate, and you may gain or lose money.

The contents of the Platform may contain forward-looking statements that are based on management's beliefs, assumptions, current expectations, estimates, and projections about the financial industry, the economy, or Global Predictions itself. Forward-looking statements are not guarantees of the underlying expected actions or future performance and future results may differ significantly from those anticipated by the forward-looking statements. Therefore, actual results and outcomes may materially differ from what may be expressed or forecasted in such forward-looking statements.

¹ Data as of July 2024.

² Availability of tax loss harvesting depends on portfolio diversity.

³ As of November 8, 2024. The optional Cash Sweep program takes the cash sitting in your brokerage account and moves it to an FDIC-insured interest-earning deposit account. The current yield is 1.0%, rates subject to change at any time. The cash sweep program is made available in coordination with Apex Clearing Corporation. Please read the Important Disclosures for more information.

⁴ This analysis calculator tool is for illustrative purposes only and is not financial advice. We do not guarantee the accuracy of the results or their relevance to your particular circumstances. This calculator uses hypothetical historical data and does not take into account the effect of taxes on a taxable account. Hypothetical historical data is no guarantee of future performance and this calculator is not intended to predict actual performance. The input of different time periods, amounts, and fees will vary calculator results. Average ETF fee is based on the AUM weighted average of US ETFs as of September 2024, see more information. Note that you can purchase ETFs through Double, which may incur additional fees.

Full pricing details along with an FAQ can be found here

Data displayed in charts and graphics above are for illustrative purposes only and do not reflect actual investment results and are not a guarantee of future results.

By using double.finance, you accept our and . Double is only available to US residents.

See Double Finance Form ADV Part IIA for additional information. Double does not guarantee that the results of its advice, recommendations, or the objectives of its direct index or cash management strategies will be achieved. We make no assurance that the investment process will consistently lead to successful investing. Before you invest, you should carefully review and consider your investment objectives as well as the risks, charges, and expenses of the underlying securities. There is at least a $1,000 account minimum required to participate in Double's strategies, although some strategies may have higher minimums.

Double does not provide tax, or legal advice. Double's website, brokerage, and advisory services are not intended for persons of any jurisdiction where Double is not authorized to do business. Tax savings will vary from client to client due to many factors including market conditions, tax characteristics of securities, client-imposed investment restrictions, client tax rate or status, and changes in tax regulations.